


Product Name	: Asciminib
Synonyms	: ABL-001
Cat No.	: M12066
CAS Number	: 1492952-76-7
Molecular Formula	: C ₂₀ H ₁₈ ClF ₂ N ₅ O ₃
Formula Weight	: 449.84
Chemical Name	: (R)-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide



Description : Asciminib (ABL-001) is a potent and selective allosteric ABL1 inhibitor with IC₅₀ of 0.25 nM in BCR-ABL1-transformed BaF3 cells; binds (K_d=0.5-0.8 nM) to the myristoyl pocket of ABL1 and induces the formation of an inactive kinase conformation; inhibits phosphorylation of both STAT5 (Tyr694; pSTAT5) and BCR-ABL1 (Tyr245; pBCR-ABL1), and shows selective activity against all BCR-ABL1 cell lines (IC₅₀=1-20 nM); retains activity against mutated ABL-1 Thr315Ile at low nanomolar concentrations; active in vivo, moderate oral absorption. Blood Cancer Phase 3 Clinical

Pathway : Angiogenesis

Target : Bcr-Abl

Receptor : Bcr-Abl

Solubility : DMSO: 50 mg/mL; Water: Insoluble (< 1 mg/ml refers to the product slightly soluble or insoluble)

SMILES : C1CN(CC1O)C2=C(C=C(C(=N2)C(=O)NC3=CC=C(C(=C3)OC(F)(F)Cl)C4=CC=NN4

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1. Wylie AA, et al. Nature. 2017 Mar 30;543(7647):733-737. 2. Lee BJ, et al. Leukemia. 2017 May;31(5):1096-1107.